108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
奥马珠单抗联合变应原特异性免疫治疗中重度过敏性哮喘的疗效和安全性：一项中国人群的前瞻性队列研究
Authors Liu N, Jin P , Li X , Gao T, Sun Y, Zhang N, Zhang Y, Liu P, Zhang H , Zhi L
Received 16 April 2025
Accepted for publication 30 August 2025
Published 23 September 2025 Volume 2025:18 Pages 1337—1346
DOI https://doi.org/10.2147/JAA.S530738
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Agnès Hamzaoui
Na Liu,1,* Peng Jin,2,* Xu Li,1 Tingting Gao,1 Yan Sun,1 Na Zhang,1 Yunqing Zhang,1 Peize Liu,1,3 Hailing Zhang,2 Lili Zhi1
1Department of Allergy, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, People’s Republic of China; 2Department of Otolaryngology, The Second Qilu Hospital of Shandong University, Jinan, 250033, People’s Republic of China; 3Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lili Zhi Department of Allergy, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, The First Affiliated Hospital of Shandong First Medical University, No. 16766, Jingshi Road, Jinan, Shandong, 250014, People’s Republic of China, Email qfsyyallergy@163.com Hailing Zhang Department of Otolaryngology, The Second Qilu Hospital of Shandong University, 247 Beiyuan Avenue, Jinan, 250033, People’s Republic of China, Email 15853138360@163.com
Background: Moderate-to-severe allergic asthma caused by dust mite sensitization is challenging to treat. Allergen-specific immunotherapy (AIT) is the only disease-modifying option but is limited by delayed effects, allergic side reactions, and poor adherence. Omalizumab, an anti-IgE antibody, may improve AIT’s safety and effectiveness.
Objective: To assess whether combining omalizumab with AIT is more effective and safer than AIT alone in patients with dust mite-induced moderate-to-severe asthma.
Methods: This prospective study involved 37 patients divided into two groups: AIT alone (n=18) and omalizumab + AIT (n=19). Over 48 weeks, asthma control (ACT, ACQ), lung function (FEV₁%, PEF%, FEV₁/FVC), and airway inflammation (FeNO) were measured. Secondary outcomes included IgE levels, eosinophil counts, quality of life (AQLQ), and safety.
Results: Both groups improved, but the combination group showed significantly better asthma control, lung function, and quality of life at week 48. Only the combination group had significant reductions in FeNO and eosinophils, suggesting stronger anti-inflammatory effects. IgE levels followed expected trends with no major group differences. Fewer adverse reactions occurred in the combination group; severe systemic events were reported only in the AIT-alone group.
Conclusion: Adding omalizumab to AIT significantly enhances asthma control, lung function, and inflammation reduction while improving treatment safety. This supports its role as an effective adjunct in managing moderate-to-severe dust mite-allergic asthma in Chinese patients.
Keywords: asthma, allergen immunotherapy, omalizumab, allergy, efficacy, safety, treatment
1Department of Allergy, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250014, People’s Republic of China; 2Department of Otolaryngology, The Second Qilu Hospital of Shandong University, Jinan, 250033, People’s Republic of China; 3Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lili Zhi Department of Allergy, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, The First Affiliated Hospital of Shandong First Medical University, No. 16766, Jingshi Road, Jinan, Shandong, 250014, People’s Republic of China, Email qfsyyallergy@163.com Hailing Zhang Department of Otolaryngology, The Second Qilu Hospital of Shandong University, 247 Beiyuan Avenue, Jinan, 250033, People’s Republic of China, Email 15853138360@163.com
Background: Moderate-to-severe allergic asthma caused by dust mite sensitization is challenging to treat. Allergen-specific immunotherapy (AIT) is the only disease-modifying option but is limited by delayed effects, allergic side reactions, and poor adherence. Omalizumab, an anti-IgE antibody, may improve AIT’s safety and effectiveness.
Objective: To assess whether combining omalizumab with AIT is more effective and safer than AIT alone in patients with dust mite-induced moderate-to-severe asthma.
Methods: This prospective study involved 37 patients divided into two groups: AIT alone (n=18) and omalizumab + AIT (n=19). Over 48 weeks, asthma control (ACT, ACQ), lung function (FEV₁%, PEF%, FEV₁/FVC), and airway inflammation (FeNO) were measured. Secondary outcomes included IgE levels, eosinophil counts, quality of life (AQLQ), and safety.
Results: Both groups improved, but the combination group showed significantly better asthma control, lung function, and quality of life at week 48. Only the combination group had significant reductions in FeNO and eosinophils, suggesting stronger anti-inflammatory effects. IgE levels followed expected trends with no major group differences. Fewer adverse reactions occurred in the combination group; severe systemic events were reported only in the AIT-alone group.
Conclusion: Adding omalizumab to AIT significantly enhances asthma control, lung function, and inflammation reduction while improving treatment safety. This supports its role as an effective adjunct in managing moderate-to-severe dust mite-allergic asthma in Chinese patients.
Keywords: asthma, allergen immunotherapy, omalizumab, allergy, efficacy, safety, treatment